New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
07:34 EDTRNAProsensa upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Prosena following new encouraging subset data analysis of lead drug drisapersen and full ownership potential following termination of its partnership with GlaxoSmithKline. Price target raised to $12 from $7.
News For RNA From The Last 14 Days
Check below for free stories on RNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
07:00 EDTRNATerrapinn to hold a conference
Subscribe for More Information
April 21, 2014
15:39 EDTRNALeerink's biotech analyst holds an analyst/industry conference call
Biotech Analyst Schwartz, along with a Key Opinion Leader, discuss Sarepta's announcement that the Company will file a New Drug Application for Eteplirsen before the end of 2014 and Prosensa's drugs in development for Duchenne Muscular Dystrophy on an Analyst/Industry conference call to be held on April 22 at 12:45 pm.
12:35 EDTRNASarepta surges after plans for Muscular Dystrophy drug filing
Subscribe for More Information
09:21 EDTRNAOn The Fly: Pre-Market Movers
HIGHER: Sarepta (SRPT), up 54% after announcing plans to to submit NDA for Eteplirsen by year end 2014. Shares of Prosnesa (RNA), another drugmaker working on a competing DMD drug, are up more than 12%... AstraZeneca (AZN), up 6% after the Sunday Times says that Pfizer (PFE) is considering a takeover bid for the company. Pfizer is up 1.2% following the report... Newmont Mining (NEM), up 8% after WSJ says the company and Barrick Gold (ABX) could resume merger talks as soon as today... Cbeyond (CBEY), up 39% after agreeing to be acquired for about $323M by Birch Communications... Momenta Pharma (MNTA), up 10.5% after the Supreme Court rejected Teva's (TEVA) bid to delay generic Copaxone... Nu Skin (NUS), up 5% after saying its China division will resume corporate-hosted business meetings... Micron (MU), up 4% after price target raised at Drexel Hamilton... DOWN AFTER EARNINGS: Acacia Research (ACTG), down 6%... athenahealth (ATHN), down 5.6%.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use